The TGA has approved Apellis Pharmaceuticals' SYFOVRE (pegcetacoplan) for the every-other-month treatment of adult patients with a form of age-related macular degeneration.
TGA approves Apellis therapy for a form of age-related macular degeneration
January 28, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 12, 2025 - - Latest News -
Rare Cancers Australia says election is the chance to end the ‘cancer lottery’
February 12, 2025 - - Latest News -
Specialised Therapeutics announces Thai approval of breast cancer therapy
February 12, 2025 - - Latest News -
Merck adds experienced industry executive to leadership team
February 11, 2025 - - Latest News -
Sandoz summit promotes reform to boost the use of biosimilars
February 11, 2025 - - Latest News -
AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025 - - Latest News -
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 - - Latest News